Ekkehard Leberer, Ph.D., Professor of Biochemistry Senior Life Sciences Consultant with over 30 years of experience in biotechnology and pharmaceutical industry

- University of Konstanz, 1974-1980
 - Diplomas in biology, chemistry and physics
- University of Konstanz, 1980-1986
 - PhD in biochemistry, summa cum laude
- Byk Prize from Altana AG for outstanding PhD thesis of pharmaceutical relevance
- University of Toronto, Banting and Best Department of Medical Research, 1986-1989
 - Postdoctoral research in molecular biology and genetic engineering
- National Research Council (NRC) of Canada, Biotechnology Research Institute, Montreal, 1989-1998
 - Research Officer in molecular genetics, genomics, and pharmaceutical research
 - Discovery of the p21 acitvated kinase (PAK) family of G-protein regulated protein kinases
- Habilitation in Biochemistry, University of Konstanz, 1992
- Hoechst Marion Roussel, 1998-1999
 - Head of Biotechnology Germany, Frankfurt
 - Head of The Center for Applied Genomics, Martinsried (Munich)
- Aventis, 1999-2003
 - Head of Functional Genomics Germany, Frankfurt
 - Head of The Center for Applied Genomics, Martinsried (Munich)
- Sanofi, 2003-2021
 - Global Head of Strategy and Portfolio Management, Functional Genomics, 2003-2008
 - Global Head of External Innovation, Biologics, 2008-2012
 - Head of R&D Alliance Management, Frankfurt, 2012-2021
- ELBIOCON, 2021
 - Life Sciences Consultant

Experiences

Academia

- Biochemistry, molecular biology, genetics, chemistry
- More than 60 publications in peer reviewed journals, including *Nature* and *Science* Pharmaceutical Industry
 - Pre-clinical and clinical drug development
 - Different therapeutic modalities including biopharmaceuticals (peptides, antibodies, oligonucleotides)
 - MiRNA therapeutics, pre-clinical and clinical development
 - Drug delivery systems including nanocarriers
 - Leadership in scientific collaborations and large scientific consortia (e.g. Innovative Medicines Initiative, COMPACT Consortium; www.imi.europa.eu)
 - Business strategy (business plan), and generation of spin-off companies
 - Portfolio management
 - External innovation (business development, alliance management, contracting)
 - Member in several Scientific Advisory Boards and Supervisory Boards